TY - JOUR
T1 - Pharmacokinetic study of s-1 in patients in whom inulin clearance was measured
AU - Ando, Yuichi
AU - Kawada, Kenji
AU - Inada, Megumi
AU - Morita, Sachi
AU - Mitsuma, Ayako
AU - Yasuda, Yoshinari
AU - Hiramatsu, Mariko
AU - Fujimoto, Yasushi
AU - Fujita, Ken Ichi
PY - 2012/7
Y1 - 2012/7
N2 - Objective: This pharmacokinetic study of S-1 was conducted in patients in whom glomerular filtration rate (GFR) was directly measured to explore the possibility of adjusting the S-1 dose on the basis of GFR in patients with normal or nearly normal renal function. Methods: S-1 was given to 12 patients twice daily for 28 consecutive days followed by 14 days of rest, repeated every 6 weeks. GFR was measured on the basis of inulin clearance (CLin) before the first day of treatment. Results: The area under the time-concentration curve (AUC) of 5-fluorouracil (5-FU) correlated with that of 5-chloro-2,4- dihydroxypyridine (CDHP, r = 0.750, p = 0.005). The AUC of CDHP correlated with the measured 24-hour creatinine clearance (CLcr) per subject (r = -0.620, p = 0.032), but not with the CLin (r = -0.356, p = 0.257). The AUC of 5-FU did not correlate with either the 24-hour CLcr per subject (r = -0.401, p = 0.187) or with the CLin (r = -0.300, p = 0.351). Conclusion: Dosage adjustment based on the GFR does not reduce individual variations in 5-FU concentrations among patients with normal or nearly normal renal function who receive S-1.
AB - Objective: This pharmacokinetic study of S-1 was conducted in patients in whom glomerular filtration rate (GFR) was directly measured to explore the possibility of adjusting the S-1 dose on the basis of GFR in patients with normal or nearly normal renal function. Methods: S-1 was given to 12 patients twice daily for 28 consecutive days followed by 14 days of rest, repeated every 6 weeks. GFR was measured on the basis of inulin clearance (CLin) before the first day of treatment. Results: The area under the time-concentration curve (AUC) of 5-fluorouracil (5-FU) correlated with that of 5-chloro-2,4- dihydroxypyridine (CDHP, r = 0.750, p = 0.005). The AUC of CDHP correlated with the measured 24-hour creatinine clearance (CLcr) per subject (r = -0.620, p = 0.032), but not with the CLin (r = -0.356, p = 0.257). The AUC of 5-FU did not correlate with either the 24-hour CLcr per subject (r = -0.401, p = 0.187) or with the CLin (r = -0.300, p = 0.351). Conclusion: Dosage adjustment based on the GFR does not reduce individual variations in 5-FU concentrations among patients with normal or nearly normal renal function who receive S-1.
UR - http://www.scopus.com/inward/record.url?scp=84862506637&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862506637&partnerID=8YFLogxK
U2 - 10.1159/000337232
DO - 10.1159/000337232
M3 - Article
C2 - 22722580
AN - SCOPUS:84862506637
SN - 0030-2414
VL - 83
SP - 38
EP - 44
JO - Oncology (Switzerland)
JF - Oncology (Switzerland)
IS - 1
ER -